retatrutide phase 2 trial obesity nejm 2023 triple agonist This week's most cited articles: 1. Original Article: Triple–Hormone-Receptor for — A https://t.co/jNL1GNnHPT #Endocrinology Retatrutide Peptide: The Breakthrough Triple-Hormone
Description
Every time you draw a dose from the vial, do it efficiently
Target Engagement Retatrutide engages GLP 1R, GIPR, and GCGR through direct peptide receptor binding that mimics the interaction of endogenous incretin and glucagon peptides
The STEP 4 trial published in JAMA showed that participants maintained significant weight loss over 68 weeks when continuing the medication
72 hafta sonunda en yksek doz (36 mg) grubundaki katlmclar vcut arlklarnn ortalama yzde 11.2'sini kaybetti
We want to increase their (elders) functionality, not decrease it, Liporace said
So 50 units equals 0.5mL
